Solid Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period
Solid Biosciences Inc. (SLDB) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 4.30 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-08-06
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-06-30 was 3.94K shares, a 94.26% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2026-03-31 was 362.00 shares, a 99.49% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-12-31 was 1.81K shares, a 36.72% decline year-over-year.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for the quarter ending 2025-09-30 was 53.41K shares.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 194.39K shares, a 336.63% increase from fiscal 2024.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 44.52K shares, a 18.97% decline from fiscal 2023.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 54.94K shares, a 50.40% increase from fiscal 2022.
- Solid Biosciences Inc. share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 36.53K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month |
|---|---|---|---|---|
| 2026-06-30 | 3.94K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 4.30K shares 10-Q · filed 2026-08-06 | 6.11K shares derived: sum of 3 quarters · filed 2026-08-06 | 59.53K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 362.00 shares 10-Q · filed 2026-05-12 | 2.17K shares derived: sum of 2 quarters · filed 2026-05-12 | 55.59K shares derived: sum of 3 quarters · filed 2026-05-12 | 124.21K shares derived: sum of 4 quarters · filed 2026-05-12 |
| 2025-12-31 | 1.81K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | 55.23K shares derived: sum of 2 quarters · filed 2026-03-19 | 123.85K shares derived: sum of 3 quarters · filed 2026-03-19 | 194.39K shares 10-K · filed 2026-03-19 |
| 2025-09-30 | 53.41K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-03 | 122.04K shares derived: sum of 2 quarters · filed 2025-11-03 | 192.58K shares 10-Q · filed 2025-11-03 | 195.44K shares derived: sum of 4 quarters · filed 2025-11-03 |
| 2025-06-30 | 68.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | 139.16K shares 10-Q · filed 2025-08-12 | 142.03K shares derived: sum of 3 quarters · filed 2025-08-12 | 142.03K shares derived: sum of 4 quarters · filed 2025-08-12 |
| 2025-03-31 | 70.54K shares 10-Q · filed 2025-05-15 | 73.40K shares derived: sum of 2 quarters · filed 2025-05-15 | 73.40K shares derived: sum of 3 quarters · filed 2025-05-15 | |
| 2024-12-31 | 2.86K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 2.86K shares derived: sum of 2 quarters · filed 2025-03-06 | 44.52K shares 10-K · filed 2025-03-06 | |
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 41.66K shares 10-Q · filed 2024-11-06 | ||
| 2024-06-30 | 41.66K shares 10-Q · filed 2024-08-13 | |||
| 2023-12-31 | 54.94K shares 10-K · filed 2024-03-13 | |||
| 2022-12-31 | 36.53K shares 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |